Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharm Holdings (NQ: TNXP )

0.2042 +0.0142 (+7.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tonix Pharm Holdings

< Previous 1 2 Next >
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at Winter 2024 Investor Summit
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Phase 3 Success for TNX-102 SL in Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
Jessica Edgar Morris, COO of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), to Present at NobleCon20
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Rapid-Relief Migraine Treatments for Urgent Needs
Via Investor Brand Network
Exposures Product Safety
As Research Into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL
Via ACCESSWIRE
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Promising Data on TNX-801 Vaccine for Mpox and Smallpox
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits NDA for Fibromyalgia Treatment and Advances Mpox Vaccine Development
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Kenya Medical Research Institute Partner on Phase I Trial for Mpox and Smallpox Vaccine TNX-801
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Promising Mpox Vaccine Data at World Vaccine Congress
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at BIO-Europe in Stockholm
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at ThinkEquity Conference
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Mpox Vaccine Research at World Vaccine Congress Europe 2024
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives First Payment from U.S. Defense Agency to Develop Broad-Spectrum Antiviral Agents
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits New Drug Application to FDA for TNX-102 SL for Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), X-Chem to Collaborate in Development of Broad-Spectrum Antivirals
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Featured in Post Discussing Nonaddictive Painkillers Designed to Counter Opioid Crisis
Via Investor Brand Network
Exposures Product Safety
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop
Via Investor Brand Network
Exposures COVID-19 Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) Receives New US Patent for Subcutaneous Administration of Zembrace(R) SymTouch(R) to Treat Migraines
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Participate in Global Conference with Three TNX-102 SL Data Presentations
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) TNX-801 Positioned as Viable Contender in Global Fight Against Mpox
Via Investor Brand Network
Exposures Product Safety
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports TNX-801 Aligns with WHO Preferred TPP for Mpox Vaccines
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Names Seasoned Veteran as New EVP of Commercial Operations
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data Demonstrating TNX-801’s Single-Dose Immune Protection Against Mpox
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Educational Campaign to Inspire Patients to Optimize Migraine Treatment Plans with Non-Oral Medication
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia
Via Investor Brand Network
Exposures Product Safety
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801
World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) for the second time in two years Worldwide availability and... 
Via FinancialNewsMedia
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.